CMT Cellex Manufacturing Transports and Logistics GmbH is a biopharmaceutical company based in Cologne that provides services in the field of cell therapy worldwide. Its offerings include organizing, manufacturing, testing and placing cell therapy products on the market both in the GMP facility “Cellex Cell Manufacturing Plant” (CCMP) and in a GMP training center. The company operates an audited and inspected GMP facility including a quality control laboratory; equipment runs with functionally closed sterile single-use kits, is fully qualified and all methods are validated; a GxP-compliant quality management system is maintained. In addition, CMT provides tailored transport and logistics solutions and serves national as well as international customers.
die Herstellung, die Prüfung und das Inverkehrbringen von Zelltherapieprodukten und alle mit diesen Leistungen im Zusammenhang stehenden organisatorischen Aufgaben wie die Transporte und Versendungen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 81446 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Armin Ehninger | Geschäftsführer(in) | Dresden |
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 81446 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2020 | Rohergebnis€7.5M2 | €0 | €7,208,620 | 82 |
| 2019 | Rohergebnis€5.2M2 | €0 | €7,761,057 | 69 |
| 2018 | ≤ €12M1 | €0 | €6,425,305 | 42 |
| 2017 | small company1 | — | €736,557 | 34 |
| 2016 | small company1 | — | €284,653 | 57 |
| 2015 | small company1 | — | €362,417 | — |
| 2014 | — | — | €173,289 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 81446 (as of 31 October 2026)
Bionic Medizintechnik GmbH
Friedrichsdorf · Herstellung von pharmazeutischen Grundstoffen
BODY PRODUCTS RELAX Pharma und Kosmetik GmbH
Frechen · Herstellung von medizinischen und zahnmedizinischen Apparaten und Materialien a. n. g.
Sintetica GmbH
Münster · Herstellung von pharmazeutischen Grundstoffen
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €3,453,415 | 86.9% |
| Depreciation | €418,960 | 10.5% |
| Interest & Similar | €101,926 | 2.6% |
